Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Topical imiquimod.

G W Pearson¹, R G Langley

¹Massachusetts General Hospital, Harvard Medical School, Dermatology Clinical Investigations Unit, Cambridge St, MA, Boston, USA.

The Journal of Dermatological Treatment

|August 13, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensus.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024

Same author

Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Same author

Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.

The British journal of dermatology·2021

Same author

Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).

The British journal of dermatology·2021

Same author

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.

The British journal of dermatology·2020

Same author

Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.

The British journal of dermatology·2020

Topical imiquimod effectively treats skin conditions like condylomata and molluscum. This review highlights its immunologic actions on monocytes and macrophages, suggesting future therapeutic potential.

Area of Science:

Immunology
Dermatology
Pharmacology

Background:

Imiquimod is a topical immune response modifier.
Its mechanism involves direct actions on immune cells.
Cytokine induction plays a key role in its effects.

Purpose of the Study:

To review the current applications of imiquimod.
To discuss the immunologic basis for imiquimod's efficacy.
To explore future therapeutic potential of imiquimod.

Main Methods:

Literature review of imiquimod studies.
Analysis of imiquimod's effects on monocytes and macrophages.
Summary of clinical outcomes for approved indications.

Main Results:

Related Experiment Videos

Topical imiquimod is an established treatment for condylomata acuminata.
Imiquimod is also effective for molluscum contagiosum.
The drug modulates immune cell function and cytokine production.

Conclusions:

Imiquimod demonstrates significant therapeutic value in dermatology.
Its immunomodulatory properties support its efficacy.
Further applications of imiquimod are anticipated.